CD40LG and rheumatoid arthritis: Whether IgM anti-PC antibodies may be a part of the explanation of lower CV risk in seronegative RA and whether genetic determinants and epigenetic modifications are involved in the activation of the atheroprotective function of these antibodies are not known.